> CLINICAL RESULTS
GENERALITIES:
2 hours after application of the patch containing Sensibio Erycontrol, the results showed:
-A significant decrease of -46% (1) of redness compared to the application of the patch without Crealine / Sensibio Erycontrol.
After 2 hours, Sensibio Erycontrol significantly increases in the skin's hydration rate (+50.8%* vs T0). This effect continues to persist 8 hours later (+27.3%) (2)
ACTION ON PAIN
Sensibio Erycontrol reduces the pain felt by patients. It relieves the sensations of discomfort (6) and smoothes the skin (5) for more than 80% of patients with dry or very dry skin.
This is achieved, among other things, through the action of AntalgicineTM, a synthetic biomimetic lipopeptide. This dipeptide is the acetylated form of a peptide naturally present in the body: Kyotorphine, which interferes with the perception of pain. Kyotorphine has its own cellular receptors which activate an incoming calcium flow (IP3 gate) and cause a release of Met-enkephalin, thus inhibiting pain.
In addition, in vitro studies on keratynocytes have shown that the addition of Antalgicine stimulates the synthesis of POMC, a precursor of endorphins and enkephalins.
ACTION ON CANCER PATIENT
After 56 days of use of Sensibio Erycontrol twice daily on face, neck, neckline and upper back, the results showed: (3)
Time to onset of acneiform skin lesions: 92% of the patients did not presented acneiform skin lesions, whatever the grade, during the study follow-up visits.
Incidence of acneiform skin lesions: no patient presented grade 1, 2, 3 or 4 acneiforms skin lesions during the study follow-up visits.
Evolution of redness and dryness severity: 94% of the patients did not present redness or dryness during the study follow-up visits.
Evolution of pain and itching intensity: no patient declared having pain or itching during the study follow-up visits.
An assessment was conducted with the 10-point analogical pain and itching rating scale. No subjects experienced such symptoms during the follow-up visits of the study (3)
Sensibio Erycontrol application reduced by approximately 90% the risk of developing of acneiform skin lesions.
TOLERANCE
Sensibio Erycontrol was very well tolerated on the ocular and cutaneous levels. (5)
*p< 0,005, Student Test, after 2 or 8 hours.
> PATIENTS FEEDBACKS
After 28 days, the skin is considered soothed and more comfortable for more than 80% of patients (4).
For 94% of patients, redness was reduced after 28 days of application of the product (5).
For 100% of the volunteers, the texture is pleasant and provides good hydration of the skin. The smell is also judged neutral (6).
More than 90% of the volunteers underline a reduction of the feeling of tightness (6).
1)Biometrological evaluation of Sensibio Erycontrol of the soothing and anti-redness effect – 20 volunteers (aged 19 to 49 years old) after 18 hours of wearing the patch and 6 hours after its removal. Dermscan France. 2019
2)Evaluation of Sensibio Erycontrol of cutation hydration rate by corneometric – 10 volunteers (aged 32 to 67 years old) with dry skin or moderated skin after only one application. France. 2019
3)Efficacy and tolerance assessment of Sensibio Erycontrol against acneiform skin lesions induced by anti-tumoral treatments with skin lesions, sensitives, redness and dryness – 36 patients (aged 22- 77 years old) after twice daily application. Georgia. 2020
4)User test under dermatological control on /Sensibio Erycontrol with phototype II to IV and dry skin on the face - 23 volunteers (27-67 years old). France. 2019
5)User test on Sensibio Erycontrol - 20 volunteers (aged 24-69 years old) with dry to very dry skin. France. 2019
6)User test on Sensibio Erycontrol - 100 volunteers (aged 18-69) with dry and sensitive skin on the face with 2 weeks of application. Bulgaria. 2019
